MRI predictors of clinical success in MR-guided focused ultrasound (MRgFUS
) treatments of uterine fibroids: results from a single centre.
VIM thalamotomy is considered if patients have medication-refractory moderate-to-severe tremor [10, 11, 13].
Compared to other treatment options, MRgFUS
represents a safe, effective, and noninvasive approach that maybe alternatively used as a fertility-preserving technique in selected cases .
During the last few years there has been an expansion in research in MRgFUS
One other study of MRgFUS
on canine and human patients has been published, but the human feasibility study used a transurethral device and targeted only the central prostate without a specific cancer target.[sup.7] There have been several reports at clinical meetings of non-North American patients treated with ExAblate MRgFUS
, but no peer-reviewed publications.
In the study, researchers surveyed a total of 197 women who underwent hysterectomy (62), UAE (74) and MRgFUS
(61) for symptomatic uterine fibroids between 2004 and 2006.
A total of 125 patients were scheduled for MRgFUS
at the Mayo Clinic between March 2005 and September 2008.
, high-intensity focused ultrasound is used during an MR scan to thermally destroy pathogenic tissue--in this case, fibroids.
Two other commonly used treatment modalities for uterine fibroids are MRgFUS
and operative hysteroscopy.
Food and Drug Administration (FDA) - approved system to use the breakthrough MR-guided Focused Ultrasound (MRgFUS
) technology that combines MRI -- to visualize tissues in the body, plan the treatment and monitor, in real time, treatment outcome -- and high intensity focused ultrasound to thermally ablate tissue.